ProPhase Labs (NASDAQ:PRPH) Downgraded by TheStreet

ProPhase Labs (NASDAQ:PRPH – Get Rating) was downgraded by equities researchers at TheStreet from a “b-” rating to a “c+” rating in a note issued to investors on Tuesday, TheStreetRatingsTable reports.

Several other brokerages have also weighed in on PRPH. HC Wainwright cut their target price on ProPhase Labs from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday. Zacks Investment Research raised ProPhase Labs from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Tuesday, February 22nd. Finally, StockNews.com began coverage on ProPhase Labs in a research note on Friday, May 13th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.88.

NASDAQ:PRPH opened at $7.67 on Tuesday. The stock’s fifty day moving average is $7.31 and its two-hundred day moving average is $6.95. ProPhase Labs has a 52 week low of $4.44 and a 52 week high of $8.58. The company has a quick ratio of 3.65, a current ratio of 3.67 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $118.81 million and a P/E ratio of 7.59.

Several large investors have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of ProPhase Labs by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 105,857 shares of the company’s stock worth $550,000 after buying an additional 3,152 shares in the last quarter. BlackRock Inc. lifted its holdings in ProPhase Labs by 14.5% in the third quarter. BlackRock Inc. now owns 28,778 shares of the company’s stock valued at $150,000 after acquiring an additional 3,647 shares during the period. State Street Corp boosted its position in shares of ProPhase Labs by 14.2% during the 1st quarter. State Street Corp now owns 31,063 shares of the company’s stock worth $217,000 after purchasing an additional 3,868 shares in the last quarter. Morgan Stanley grew its stake in shares of ProPhase Labs by 354.6% during the 1st quarter. Morgan Stanley now owns 10,592 shares of the company’s stock worth $78,000 after purchasing an additional 8,262 shares during the period. Finally, Perritt Capital Management Inc. increased its holdings in shares of ProPhase Labs by 5.9% in the 3rd quarter. Perritt Capital Management Inc. now owns 188,400 shares of the company’s stock valued at $980,000 after purchasing an additional 10,500 shares in the last quarter. 9.75% of the stock is currently owned by institutional investors and hedge funds.

ProPhase Labs Company Profile (Get Rating)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Read More